Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group performance status 0 or 1
You may not be if
Measurable disease at baseline as per RECIST version 1.1
Life expectancy of greater than or equal to (\>=) 16 weeks
Adequate bone marrow, liver, cardiac, and renal function
Negative serum pregnancy test within 7 days prior to study treatment in premenopausal women and women less than or equal to (\<=) 12 months post-menopause. Postmenopausal state is defined as amenorrhea for greater than (\>) 12 months.
Allergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulation
Active or untreated central nervous system (CNS) metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening (within 28 days before C1D1) and prior radiographic assessments. Participants with radiographically stable, asymptomatic previously irradiated lesions are eligible provided participant is \>= 4 weeks beyond completion of cranial irradiation and \>= 3 weeks off of corticosteroid therapy. Participants with metastases to the brain stem, midbrain, pons, medulla, or within 10 millimeter (mm) of the optic apparatus (optic nerves and chiasm) are completely excluded
Leptomeningeal disease
History of or active autoimmune disease
Evidence of significant, uncontrolled concomitant diseases, which could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or pulmonary disease (including obstructive pulmonary disease and history of symptomatic bronchospasm)
Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the exceptions provided in the protocol
Prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first receipt of study drug
Prior toxicities from chemotherapy, radiotherapy, and other anti-cancer therapies, including immunotherapy that have not regressed to Grade \<=1 severity (Common Terminology Criteria for Adverse Events \[CTCAE\] v4.03, or later versions)
History of human immunodeficiency virus (HIV)
Participants with active hepatitis B, active hepatitis C, or active tuberculosis
Participant has had pulmonary embolism or any other thrombo-embolic event within 6 months prior to study entry
Participants has a history of hematological malignancy within the last 5 years prior to study entry
Treatment with systemic immunosuppressive medications - Pregnant or lactating women
